Other Information
−Removed: Exchange Act Section 3(r) Disclosure
−Removed: Medtronic has engaged in certain activities that it is required to disclose pursuant to Section 13(r)(1)(D)(ii) of the Securities Exchange Act of 1934, as amended.
−Removed: In particular, during the first quarter of fiscal year 2025, Medtronic engaged in certain regulatory activities involving Russia’s Federal Security Service (“FSB”) related to its medical devices that were expressly authorized by the U.S.
−Removed: Government under applicable economic sanctions regulations.
−Removed: During the first quarter of fiscal year 2025 ending July 26, 2024, in the normal course of business and consistent with the Office of Foreign Assets Control ("OFAC") authorizations as in effect at the time, Medtronic Russia filed one notification with the FSB, as required under local Russian law for the import of medical devices that make use of encryption functionality.
−Removed: This activity did not directly result in any revenues or profits for Medtronic.
−Removed: To the extent that notifications with the FSB remain permissible under U.S.
−Removed: law, Medtronic may decide to continue engaging in such activities for the limited purposes of complying with local law requirements in Russia.
Rule 10b5-1 Director and Officer Trading Arrangements
−Removed: During the quarter ended July 26, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.
+Added: During the three months ended October 25, 2024, certain of our officers and directors adopted “Rule 10b5-1 trading arrangements,” intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act as follows.
+Added: On October 10, 2024 , Brett Wall , Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan.
+Added: Wall's trading plan provides for the sale of up to 22,287 shares of the Company's common stock prior to the plan's August 1, 2025 termination date.
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
Medtronic plc
−Removed: August 27, 2024 /s/ Jennifer M.
+Added: November 26, 2024 /s/ Jennifer M.
Senior Vice President, Global Controller and Chief Accounting Officer (Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.